Literature DB >> 14531041

Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.

Werner Poewe1, Christoph Scherfler.   

Abstract

We discuss the potential role of dopamine transporter (DAT) imaging by single photon emission computed tomography (SPECT) as a biological marker for differentiating among parkinsonian disorders in routine clinical practice, and the implication for disease progression assessment is considered. Although clinical criteria enable accurate and reliable diagnosis of fully developed Parkinson's disease, there are several areas of diagnostic uncertainty relating to atypical parkinsonian disorders, isolated tremor symptoms not fulfilling essential tremor criteria, as well as drug-induced and psychogenetic parkinsonism. DAT-SPECT facilitates differential diagnosis of the different parkinsonian syndromes that cannot be reliably separated on clinical grounds and it can thus provide valuable diagnostic information in early disease. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531041     DOI: 10.1002/mds.10573

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

1.  Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer's disease.

Authors:  Tabea H Schauer; Maximilian Lochner; Gabor G Kovacs
Journal:  J Neural Transm (Vienna)       Date:  2012-06-05       Impact factor: 3.575

2.  The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study.

Authors:  Kimberly D Seifert; Jonathan I Wiener
Journal:  Am J Neurodegener Dis       Date:  2013-03-08

3.  Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [123I]beta-CIT SPECT analysis.

Authors:  Christoph Scherfler; Sylvia M Boesch; Eveline Donnemiller; Klaus Seppi; Helga Weirich-Schwaiger; Georg Goebel; Irene Virgolini; Gregor K Wenning; Werner Poewe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-13       Impact factor: 9.236

Review 4.  Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism.

Authors:  Hae-Won Shin; Sang-Wook Hong; Young Chul Youn
Journal:  J Clin Neurol       Date:  2022-05       Impact factor: 2.566

Review 5.  Dopamine transporter (DAT) imaging in Parkinson's disease and related disorders.

Authors:  Thomas Brücke; Christof Brücke
Journal:  J Neural Transm (Vienna)       Date:  2021-12-15       Impact factor: 3.850

6.  Synthesis, radiosynthesis and in vivo evaluation of [I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine as a selective tracer for imaging the dopamine transporter.

Authors:  S De Bruyne; T L Boos; L Wyffels; J L Goeman; K C Rice; F De Vos
Journal:  J Labelled Comp Radiopharm       Date:  2009-05-28       Impact factor: 1.921

7.  Eye of the tiger-like MRI in parkinsonian variant of multiple system atrophy.

Authors:  Ming-Hong Chang; Wan-Ling Hung; Yi-Chu Liao; Yi-Chung Lee; Peiyuan F Hsieh
Journal:  J Neural Transm (Vienna)       Date:  2009-05-07       Impact factor: 3.575

8.  Drug-induced parkinsonism.

Authors:  Hae-Won Shin; Sun Ju Chung
Journal:  J Clin Neurol       Date:  2012-03-31       Impact factor: 3.077

9.  Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center.

Authors:  Srivadee Oravivattanakul; Lucas Benchaya; Guiyun Wu; Anwar Ahmed; Ilia Itin; Scott Cooper; Michal Gostkowski; Joseph Rudolph; Kristin Appleby; Patrick Sweeney; Hubert H Fernandez
Journal:  Mov Disord Clin Pract       Date:  2015-10-28

10.  Substantia Nigra Echogenicity Predicts Response to Drug Withdrawal in Suspected Drug-Induced Parkinsonism.

Authors:  Jose L López-Sendón Moreno; Araceli Alonso-Cánovas; Javier Buisán Catevilla; Nuria García Barragán; Iñigo Corral Corral; Alicia de Felipe Mimbrera; María Consuelo Matute Lozano; Jaime Masjuan Vallejo; Juan Carlos Martínez-Castrillo
Journal:  Mov Disord Clin Pract       Date:  2015-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.